CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

Terry J. Fry(National Institutes of Health), Nirali N. Shah(National Institutes of Health), Rimas J. Orentas(National Institutes of Health), Maryalice Stetler‐Stevenson(Center for Cancer Research), Constance M. Yuan(Center for Cancer Research), Sneha Ramakrishna(National Institutes of Health), Pamela L. Wolters(National Institutes of Health), Staci Martin(National Institutes of Health), Cindy Delbrook(National Institutes of Health), Bonnie Yates(National Institutes of Health), Haneen Shalabi(National Institutes of Health), Thomas J. Fountaine(National Institutes of Health), Jack F. Shern(National Institutes of Health), Robbie G. Majzner(Stanford University), David F. Stroncek(National Institutes of Health Clinical Center), Marianna Sabatino(National Institutes of Health Clinical Center), Yang Feng(National Cancer Institute), Dimiter S. Dimitrov(National Cancer Institute), Ling Zhang(National Institutes of Health), Sang M. Nguyen(National Institutes of Health), Haiying Qin(National Institutes of Health), Boro Dropulić(Lentigen Technology (United States)), Daniel W Lee(National Institutes of Health), Crystal L. Mackall(Stanford University)
Nature Medicine
November 20, 2017
Cited by 1,337

Abstract


Related Papers

No related papers found

Powered by citation graph analysis